Sign In
Buy IKT
$1.70
-0.0100 (-0.585%)
At Close: Jun 02, 2026
Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
04:12pm, Thursday, 20'th Nov 2025
BOSTON and ATLANTA, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics t
Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension
04:01pm, Thursday, 20'th Nov 2025
Phase 3 Study initiating in First Quarter of 2026 Single Pivotal Study Accelerates Potential FDA Approval Timeline by Approximately 3 Years BOSTON and ATLANTA, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibi
Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity
04:01pm, Friday, 14'th Nov 2025
BOSTON and ATLANTA, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics t
Inhibikase Therapeutics (NYSE:IKT) Trading Down 0.6% – What’s Next?
02:52am, Friday, 24'th Oct 2025
Inhibikase Therapeutics, Inc. (NYSE: IKT - Get Free Report)'s share price fell 0.6% during mid-day trading on Thursday. The company traded as low as $1.50 and last traded at $1.53. 20,281 shares were
Inhibikase Therapeutics (NASDAQ:IKT) versus Prime Medicine (NASDAQ:PRME) Head-To-Head Contrast
01:32am, Wednesday, 22'nd Oct 2025
Prime Medicine (NASDAQ: PRME - Get Free Report) and Inhibikase Therapeutics (NASDAQ: IKT - Get Free Report) are both small-cap manufacturing companies, but which is the superior business? We will comp
Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer
08:00am, Tuesday, 19'th Aug 2025
BOSTON and ATLANTA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics t
Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity
04:50pm, Thursday, 14'th Aug 2025
BOSTON and ATLANTA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics t
Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity
04:05pm, Wednesday, 14'th May 2025
Advancing IKT-001 into a Late-Stage Clinical Trial Program in Pulmonary Arterial Hypertension Advancing IKT-001 into a Late-Stage Clinical Trial Program in Pulmonary Arterial Hypertension
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Inhibikase Therapeutics, Inc. (NASDAQ: IKT)
08:30am, Monday, 05'th May 2025
NEW YORK , May 5, 2025 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Inhibikase Therapeutics, Inc. (NASDAQ: IKT) on behalf of the company's shareholders. The investigation
Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer
08:00am, Monday, 14'th Apr 2025
BOSTON and ATLANTA, April 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company innovating small molecul
Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity
04:01pm, Thursday, 27'th Mar 2025
New Leadership and Focus on Advancement of IkT-001 into a Late-Stage Clinical Trial Program in Pulmonary Arterial Hypertension New Leadership and Focus on Advancement of IkT-001 into a Late-Stage Clin
Inhibikase Therapeutics (IKT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
10:56am, Wednesday, 05'th Mar 2025
Inhibikase Therapeutics (IKT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions c
Inhibikase Announces Expansion of Senior Leadership Team
08:00am, Monday, 24'th Feb 2025
--- Chris Cabell, MD MHS FACC Appointed President and Head of Research & Development --- --- John Adams, PhD Appointed Chief Scientific Officer --- --- Vince Aurentz to join Inhibikase Board of Direct
Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company's Growth
08:00am, Tuesday, 18'th Feb 2025
-- Mr. Iwicki Brings Track Record of Operational Excellence and Significant Expertise in PAH and Cardiovascular Diseases -- -- Amit Munshi Appointed Chair of the Board of Directors -- BOSTON, Feb. 18,
Inhibikase Therapeutics stops Parkinson's drug development as it fails to show benefits in study
06:30pm, Wednesday, 29'th Jan 2025
Inhibikase Therapeutics said on Wednesday it would stop development of its experimental Parkinson's disease drug after it failed to improve patients' ability to carry out daily tasks such as eating an
